STOCK TITAN

Cybin Inc. - CYBN STOCK NEWS

Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.

Cybin Inc. (symbol: CYBN) is a pioneering biopharmaceutical company dedicated to addressing mental health challenges through innovative therapeutics. Specializing in psychedelic-based therapies, Cybin focuses on developing novel compounds, delivery mechanisms, and protocols aimed at treating a range of psychiatric and neurological conditions.

Cybin's core business revolves around advancing clinical-stage programs designed to harness the potential of psychedelics. The company is engaged in creating safe and effective treatments for conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD). Their research and development efforts highlight the transformative potential of these therapies in modern medicine.

Recently, Cybin has achieved significant milestones, including progress in their proprietary drug delivery technologies. These advancements aim to improve the administration and efficacy of psychedelic compounds, ensuring patients receive the maximum therapeutic benefit. Their innovative approach extends to developing new chemical entities (NCEs) that hold promise in the field of mental health treatment.

Financially, Cybin remains robust and committed to its growth strategy. The company has secured strategic partnerships and collaborations that bolster its research initiatives and clinical trials. These alliances are crucial in accelerating the development and commercialization of their therapeutic solutions.

Cybin's product pipeline is impressive, featuring multiple candidates in various stages of development. These include CYB001, a formulation targeting major depressive disorder, and CYB003, designed for anxiety disorders. Each product undergoes rigorous testing to ensure safety and effectiveness.

In summary, Cybin Inc. is at the forefront of revolutionizing mental health treatment through psychedelic-based therapies. Their dedication to advancing science and addressing unmet medical needs positions them as a significant player in the biopharmaceutical industry.

Rhea-AI Summary
Cybin Inc. announces agreement with Fluence to support the streamlining and scaling of its EMBARK facilitator training program for a Phase 3 trial of CYB003 for major depressive disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.94%
Tags
-
Rhea-AI Summary
Cybin Inc. CEO to participate in panel discussion at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.55%
Tags
conferences
-
Rhea-AI Summary
Cybin Inc. announces virtual 2023 Annual and Special Meeting of Shareholders on October 12, 2023 at 1:00 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.24%
Tags
none
Rhea-AI Summary
Cybin completes enrollment in Phase 2 study of CYB003 for major depressive disorder, with positive safety profile and no serious adverse events. Plans to scale to Phase 3 study in early 2024. Anticipates potential Breakthrough Therapy designation in Q4 2023. Acquisition of Small Pharma Inc. expected to close in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.02%
Tags
-
Rhea-AI Summary
Cybin Inc. has been granted a U.S. patent for deuterated tryptamine compounds, strengthening their position in the psychedelic drug development sector. The patent covers deuterated 5-methoxy-dimethyltryptamine analogs and provides exclusivity until 2041. This adds to their impressive intellectual property portfolio of 29 granted patents and over 150 pending patents. The company's recent acquisition of Small Pharma Inc. further enhances their position. Upcoming milestones include Phase 1 data in 2023 and Phase 2 efficacy studies in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
none
-
News
Rhea-AI Summary
Cybin Inc. and Small Pharma Inc. have entered into a definitive arrangement agreement for Cybin to acquire all of Small Pharma's issued and outstanding securities in an all-share transaction. The exchange ratio implies consideration of approximately $0.10 per Small Pharma Share, representing a 43.6% premium. The combined entity will create an international clinical-stage leader in novel psychedelic therapeutics with the largest intellectual property portfolio in the sector. The transaction is expected to close in late October 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
News
Rhea-AI Summary
Cybin to acquire Small Pharma in all-share transaction, creating a leader in psychedelic therapeutics. Small Pharma shareholders to receive 0.2409 Cybin Shares for each Small Pharma Share held, representing a 43.64% premium. Combined company will have the largest IP portfolio in the psychedelic drug development sector with 28 granted patents and 158 pending patents. Cybin expects to report Phase 2 safety and efficacy data for CYB003 in late 2023. Transaction expected to close in late October 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
-
Rhea-AI Summary
Cybin Inc. renews its at-the-market equity program, allowing the issuance and sale of up to US$35,000,000 of common shares. The net proceeds will be used for growth opportunities and working capital initiatives. The program will be effective until all shares are sold or September 17, 2025. No assurance on completion of sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Cybin Inc. has initiated preparations for good manufacturing practices production of a capsule formulation of CYB003, its deuterated psilocybin analog for the potential treatment of Major Depressive Disorder (MDD). The capsule formulation is designed to be stable, dose flexible, patient-friendly, and commercially scalable. Shipments of CYB003 capsules to clinical sites are expected in Q1 2024. The company has also been granted a U.S. patent that covers composition of matter claims and treatment methods for its CYB003 program until 2041.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none

FAQ

What is the current stock price of Cybin (CYBN)?

The current stock price of Cybin (CYBN) is $10.15 as of November 5, 2024.

What is the market cap of Cybin (CYBN)?

The market cap of Cybin (CYBN) is approximately 202.3M.

What is Cybin Inc.?

Cybin Inc. is a biopharmaceutical company focused on developing psychedelic-based therapies for treating mental health conditions.

What does Cybin Inc. specialize in?

Cybin specializes in creating safe and effective treatments using psychedelic compounds to address psychiatric and neurological conditions.

What are the core areas of Cybin's research?

Cybin's research focuses on advancing psychedelic-based therapies, developing novel compounds, and improving drug delivery mechanisms.

What recent achievements has Cybin Inc. made?

Cybin has made significant progress in drug delivery technologies and the development of new chemical entities for mental health treatment.

Can you name some of Cybin's product candidates?

Cybin's pipeline includes CYB001 for major depressive disorder and CYB003 for anxiety disorders, among other candidates.

How does Cybin contribute to mental health treatment?

Cybin contributes by developing innovative psychedelic-based therapies aimed at providing effective treatments for various mental health conditions.

Has Cybin formed any strategic partnerships?

Yes, Cybin has established strategic partnerships and collaborations to support its research and clinical trials.

What is the significance of Cybin's drug delivery technologies?

Cybin's drug delivery technologies enhance the administration and therapeutic efficacy of psychedelic compounds.

What conditions are Cybin's therapies aimed at treating?

Cybin's therapies target psychiatric and neurological conditions such as depression, anxiety, and PTSD.

Where can I find the latest news about Cybin Inc.?

The latest news and updates about Cybin Inc. can be found on their official website and financial news platforms like StockTitan.

Cybin Inc.

NYSE:CYBN

CYBN Rankings

CYBN Stock Data

202.33M
19.99M
6.35%
38.41%
3.28%
Biotechnology
Healthcare
Link
United States of America
Toronto